Biograph Vision, Biograph mCT Family of PET/CTs

The Biograph Vision and Biograph mCT PET/CT systems are advanced medical imaging devices that combine X-Ray Computed Tomography (CT) for anatomical detail and Positron Emission Tomography (PET) for metabolic function, primarily for oncology, neurology, and cardiology. Recent software enhancements, including AI-driven features like OncoFreeze AI and FlowMotion AI, alongside improved scatter correction, aim to enhance image quality, workflow efficiency, and diagnostic accuracy.

The Biograph Vision and Biograph mCT PET/CT systems are hybrid imaging modalities that integrate multi-slice X-Ray Computed Tomography (CT) with Positron Emission Tomography (PET). These systems are designed for comprehensive whole-body examinations in oncology, neurology, and cardiology, providing fused high-resolution anatomical (CT) and metabolic/physiological (PET) information. The CT component generates cross-sectional images using X-ray transmission data, while the PET subsystem images the distribution of radiopharmaceuticals to assess organ function and metabolic activity, with CT also providing attenuation correction for PET and anatomical referencing. The systems support independent CT or PET imaging and are intended for use by trained healthcare professionals to detect, diagnose, stage, and monitor diseases like cancer, cardiovascular conditions, and neurological disorders, as well as to assist in radiotherapy planning and interventional procedures. The CT component is also capable of low-dose lung cancer screening. Key updates to the system software include the introduction of OncoFreeze AI for data-driven gating, FlowMotion AI for PET FAST planning, and a FAST PET workflow, alongside updates to HD FoV, PET DICOM dose reporting, and Whole Body Scatter Correction specifically for the Biograph Vision model. Performance testing, conducted according to NEMA NU2-2018 standards on various configurations of both Biograph Vision (6-ring, 8-ring) and Biograph mCT (3-ring, 4-ring) systems, demonstrated adherence to acceptance criteria for resolution, sensitivity, count rate, scatter fraction, image quality, and co-registration accuracy. Notably, OncoFreeze AI showed comparable SUV and volume measurement changes relative to static imaging as Anzai-based OncoFreeze. FlowMotion AI achieved high accuracy (87.1%-100%) in defining bed ranges. The Whole Body Scatter Correction for Biograph Vision significantly reduced errors in ROI signal representation compared to single bed scatter correction in phantom studies.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the 'OncoFreeze AI (Data Driven Gating)' compare to traditional respiratory gating methods in terms of patient comfort and scan time, beyond the reported SUV and volume measurement accuracy?; What specific patient populations or tumor types benefit most from the 'Whole Body Scatter Correction' in the Biograph Vision system, and are there scenarios where single bed scatter correction might still be preferred?; Could the 'FlowMotion AI (PET FAST Planning)' lead to a reduction in radiopharmaceutical dose or overall scan duration while maintaining diagnostic image quality across different patient body habitus?; What are the computational requirements and processing times associated with the new AI-driven features (OncoFreeze AI, FlowMotion AI), and how do these impact overall clinical workflow efficiency?; How do the updates to HD FoV and PET DICOM dose reporting specifically enhance the diagnostic capabilities or radiation safety management for the Biograph Vision and Biograph mCT systems?